FDA Hands Eli Lilly Another New Drug Rejection

Eli Lilly suffered yet another setback at the hands of U.S. regulators last Friday. The FDA told Lilly that it would need to conduct another study of a new treatment designed to help a group of patients with a pancreatic disorder before it could expect an approval.

Liprotamase, which was developed by Lilly subsidiary Alnara to help patients digest food, was intended to become the first such drug not made from pig enzymes. Instead it was designed from microbial enzymes. Reuters noted that analysts at Citi had projected peak potential earnings of $300 million. But it may be quite some time